Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.29 USD | +6.42% | +36.73% | -60.88% |
05-10 | Annovis Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-09 | Annovis Bio, Inc. Announces Unblinding of the Buntanetap Phase III Data in Parkinson?s Disease | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-60.88% | 75.43M | |
+4.84% | 111B | |
+11.18% | 105B | |
-12.18% | 22.34B | |
-3.84% | 21.93B | |
-6.13% | 18.59B | |
-36.52% | 18.12B | |
-9.78% | 16.96B | |
+2.97% | 13.7B | |
+36.40% | 12.45B |
- Stock Market
- Equities
- ANVS Stock
- News Annovis Bio, Inc.
- Maxim Group Adjusts Annovis Bio Price Target to $26 From $70, Maintains Buy Rating